B-Harmony: WuXi And MedImmune Establish JV To Seize Biologics Growth In China
This article was originally published in The Pink Sheet Daily
WuXi’s joint venture with MedImmune could have ripple effects for other multinational biotechs aiming to develop biologics for China.
You may also be interested in...
Successful biotech launches like Regeneron’s Eylea, Vertex’s Incivek and others have investors reconsidering the “short the launch” mentality that pervaded the industry a year ago, though no one is throwing caution to the wind.
Prices of direct acting hepatitis C drugs are down by 85% in China, with cancer and antidiabetes therapy costs cut by 65% and drug makers are rushing to celebrate. Scrip delves into the considerations behind the low prices and whether industry's excitement is a bit premature.
Rapid changes in China prompt many pharma companies to shuffle strategies and accelerate personal changes. BMS is getting a new country GM, Pfizer Biopharma China GM is departing and Takeda BU head is stepping down.